Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Akhurst

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJohn Violet, Price Jackson, Justin Ferdinandus, et al.
The Lancet. Oncology|May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyMichael S Hofman, John Violet, Rodney J Hicks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatmentAmir Iravani, Medhat M Osman, Alison M Weppler, et al.
BMJ Open|November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocolFiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
International Journal of Radiation Oncology, Biology, Physics|July 5, 2023
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 StudyFiona Hegi-Johnson, Stacey E Rudd, Christian W Wichmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJohn Violet, Shahneen Sandhu, Amir Iravani, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
The Lancet. Oncology|October 21, 2025
Lutetium-177 [<sup>177</sup>Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trialLouise Kostos, James P Buteau, Jing Xie, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Dosimetry of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJohn Violet, Price Jackson, Justin Ferdinandus, et al.
The Lancet. Oncology|May 13, 2018
[<sup>177</sup>Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 studyMichael S Hofman, John Violet, Rodney J Hicks, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatmentAmir Iravani, Medhat M Osman, Alison M Weppler, et al.
BMJ Open|November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocolFiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
International Journal of Radiation Oncology, Biology, Physics|July 5, 2023
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 StudyFiona Hegi-Johnson, Stacey E Rudd, Christian W Wichmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJohn Violet, Shahneen Sandhu, Amir Iravani, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2025
Prognostic Value of Initial Imaging and PSA Change with [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry AnalysisDavid C Chen, James P Buteau, Nathan Papa, et al.
The Lancet. Oncology|October 21, 2025
Lutetium-177 [<sup>177</sup>Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trialLouise Kostos, James P Buteau, Jing Xie, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
Pageof 7